Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US

February 15, 2023 · Benzinga

Israeli-based next-gen psychedelics biotech Clearmind Medicine 

CMND+0.83%+ Free Alerts together with partner clinical-stage pharma company SciSparc

SPRC-0.44%+ Free Alerts has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO).

The patents cover psychedelic-based therapeutics, including monotherapy and novel combinations of SciSparc’s CannAmide and classical psychedelics.

More specifically, the patent applications refer to proprietary combinations of LSD, psilocybin, and DMT with SciSparc’s Palmitoylethanolamide (PEA), a cannabimimetic compound and the active ingredient of its proprietary CannAmide drug.

The fruitful collaboration between both companies has previously led Clearmind to file three other U.S. patent applications, then for the combination of SciSparc’s PEA with Clearmind’s MEAI (5-methoxy-2-aminoindane) for treating Alcohol Use Disorder (AUD,) cocaine addiction, and obesity and its related metabolic disorders.

The new patent applications aim to make use of psychedelic substances that have shown positive clinical results together with CannAmide to potentially offer “a treatment that is more effective, safer, and at lower costs,” according to Clearmind CEO Adi Zuloff-Shani.

The strategy “aligns with the company’s vision to bring patients the newest, most effective treatments while maintaining a high safety profile and a strong IP position to enhance commercial viability.”

SpiSparc CEO Oz Adler says that the new patent applications continue to support the company’s findings of the major role CannAmide plays in SciSparc’s various proprietary combination treatments. 

“All our clinical and pre-clinical studies performed to date, in numerous diseases and conditions, indicated CannAmide’s ability to reduce doses while maintaining therapeutic efficacy and increasing safety,” Adler detailed. “We have great confidence in our collaboration with Clearmind and believe that together we can maximize the therapeutic effect of our products, potentially offering additional solutions for mental health problems with unmet needs that have limited effective solutions, if at all.” (Full Story)

In categories:Medical Psychedelics
Next Post

Nasdaq Gets a Healthy Dose of Psychedelics With Lucy Scientific

Lucy Scientific Discovery Inc. (Nasdaq: LSDI), which focuses on psychotropic drugs and had its initial public offering last week, rang the closing bell at the Nasdaq stock exchange today in New York. The company is focused on becoming the premier research, development, and…
Previous Post

From Perpetual Otherness To Artistic Triumph: Exploring Identity Through Psychedelic Art With SpookyGirl’s Andi Astra

Stepping into the world of illustrator Andi Astra, founder and creative director of SpookyGirl, a colorful home decor, art and apparel brand that boasts more than 150.000 social media followers, is like taking a journey to a different universe. From their…
Random Post

Erykah Bud-u: R&B Singer Announces Strain in Partnership with Cookies

R&B singer Erykah Badu is branching out into cannabis with a new strain that will be exclusively available at Cookies stores starting in Caliifornia. She discusses the Limoncello variety grown by Mad Cow Genetics and the partnership with Cookes co-founder Berner on YouTube. In the…
Random Post

Judge blocks Arkansas ban on delta-8 THC, other hemp products

In at least a temporary victory for the Arkansas hemp industry, a federal judge blocked enforcement of a recent state ban on products containing intoxicating hemp-derived cannabinoids such as delta-8 THC. Calling the ban confusing and arbitrary, U.S. District Court Judge Billy…
Random Post

New York Approves Plans to Allow Cannabis ‘Showcases’ & Sales at Public Events

New York cannabis regulators on Wednesday voted to approve a “cannabis showcase” program that would allow growers to sell products to the public at events, NBC 5 reports. The Cannabis Showcase will allow growers to partner with adult-use cannabis retailers and processors to organize events…
Random Post

Cannabis Study Breaks ‘Lazy Stoner’ Stereotype

New research shows that people who use weed are no more likely to be unmotivated compared to people who don’t. The lazy stoner stereotype has long been the go-to depiction of people who use cannabis in mainstream media and a pillar of anti-drug…